secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2025-04-28T23:59:59+00:00
Accession:  0001213900-25-035941
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada reports 90% ORR at any time point in Phase 2 NDV-01 trial for NMIBC
---------------------------------------------------------------------------

- 90% (18/20) achieved high-grade disease-free status at any time point; 85% ORR at 3 months.
- 100% complete response in CIS patients (2/2); 88.8% high-grade recurrence-free survival in papillary disease.
- NDV-01 well tolerated; no treatment-related AEs >Grade 1, no discontinuations due to AEs.
- Study continues enrolling; 26 patients enrolled, 20 reached 3-month assessment, 7 at 6 months.
- Administration time <10 minutes; data support potential bladder-sparing outpatient therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390025035941/0001213900-25-035941-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390025035941/ea0239764-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-035941

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer